Iris Scheffen - Breast Center Niederrhein, Ev. Hospital Bethesda

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 18 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Chemotherapy-free Neoadjuvant Pembrolizumab Combined with Trastuzumab and Pertuzumab in HER2-enriched Early Breast Cancer (WSG-KEYRICHED-1): a Single-Arm, Phase 2 Trial

Sherko Kuemmel, Monika Graeser,Peter Schmid,Mattea Reinisch,Friedrich Feuerhake,Valery Volk,Sorin Armeanu-Ebinger, Leon Schütz, Olga Kelemen,Christopher Schroeder,Stephan Ossowski,Katarzyna Jóźwiak,Athina Kostara,Iris Scheffen,Kerstin Lüdtke-Heckenkamp,Felix Hilpert, Angela Kentsch,Carsten Ziske, Reinhard Depenbusch,Michael Braun,Jens Uwe Blohmer,Christine Zu Eulenburg,Matthias Christgen, Stephan Bartels, Hans Heinrich Kreipe,Rachel Wuerstlein, Claudia Biehl,Enrico Pelz,Andreas Hartkopf,Nadia Harbeck,Oleg Gluz, West German Study Group investigators

The Lancet Oncologyno. 5 (2025): 629-640

Cited0Views0WOSBibtex

Neoadjuvant Dynamic Marker-Adjusted Personalized Therapy Comparing Trastuzumab-Deruxtecan Versus Pacli-/Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in HER2+ Early Breast Cancer: WSG-ADAPT-HER2-IV

Nadia Harbeck,Michael Braun,Oleg Gluz,Peter Schmid,Monika Karla Graeser,Andreas D. Hartkopf,Oliver Hoffmann,Athina Kostara,Silke Polata,Lea Louise Volmer,Raquel von Schumann,Sarah Wetzig,Stefanie Wiebe, Matthias R. Zaiss,Lotta Ada Fischer,Iris Scheffen,Matthias Christgen,Hans Heinrich Kreipe,Ulrike Nitz,Sherko Kuemmel

Journal of Clinical Oncologyno. 16_suppl (2024): TPS631-TPS631

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn